ACADIA Pharmaceuticals

ACADIA Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in related central nervous system (CNS) disorders. The Company has a pipeline of product candidates led by NUPLAZID (pimavanserin) -  the first and only medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis. Pimavanserin is also in Phase II development for Alzheimer’s disease psychosis and has successfully completed a Phase II trial in schizophrenia. ACADIA also has clinical-stage programs for glaucoma and, in collaboration with Allergan, Inc., for chronic pain.

Company Growth (employees)
Type
Public
HQ
San Diego, US
Founded
1993
Size (employees)
370 (est)
ACADIA Pharmaceuticals was founded in 1993 and is headquartered in San Diego, US

ACADIA Pharmaceuticals Office Locations

ACADIA Pharmaceuticals has an office in San Diego
San Diego, US (HQ)
3611 Valley Centre Dr, Suite 300

ACADIA Pharmaceuticals Data and Metrics

ACADIA Pharmaceuticals Financial Metrics

ACADIA Pharmaceuticals's revenue was reported to be $15.3 m in Q1, 2017
USD

Revenue (Q1, 2017)

15.3 m

Gross profit (Q1, 2017)

13 m

Gross profit margin (Q1, 2017), %

85%

Net income (Q1, 2017)

(87.8 m)

EBIT (Q1, 2017)

(88.8 m)

Market capitalization (17-Aug-2017)

3.8 b

Cash (31-Mar-2017)

157.4 m
ACADIA Pharmaceuticals's current market capitalization is $3.8 b.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

1.1 m120 k61 k17.3 m

Revenue growth, %

(90%)(49%)28311%

Cost of goods sold

3.1 m

Gross profit

14.3 m

Gross profit Margin, %

82%

R&D expense

26.7 m60.6 m73.9 m99.3 m

General and administrative expense

12.7 m32.7 m88.3 m186.5 m

Operating expense total

39.4 m93.4 m164.7 m290.1 m

EBIT

(38.3 m)(93.2 m)(164.6 m)(272.8 m)

EBIT margin, %

(3345%)(77692%)(269856%)(1574%)

Interest income

349 k755 k499 k2.8 m

Pre tax profit

(37.9 m)(92.5 m)(164.1 m)(270.1 m)

Income tax expense

330 k1.3 m

Net Income

(37.9 m)(92.5 m)(164.4 m)(271.4 m)
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

97 k5.3 m15.3 m

Cost of goods sold

526 k845 k2.3 m

Gross profit

(429 k)4.4 m13 m

Gross profit Margin, %

(442%)84%85%

R&D expense

13.8 m17 m16.3 m18.4 m18.7 m22.8 m20.5 m25.8 m35.4 m

General and administrative expense

8 m8.1 m24.3 m21.1 m20.3 m27.5 m50.8 m50.5 m65.7 m

Operating expense total

21.8 m25 m40.6 m39.5 m39 m50.3 m71.2 m76.3 m101.2 m

EBIT

(21.7 m)(25 m)(40.6 m)(39.5 m)(39 m)(50.3 m)(71.9 m)(72.4 m)(88.8 m)

EBIT margin, %

(74147%)(1374%)(581%)

Net Income

(21.5 m)(24.8 m)(40.4 m)(39.4 m)(38.9 m)(49.8 m)(71.3 m)(71.6 m)(87.8 m)
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

11.7 m61.9 m102.1 m163.6 m

Accounts Receivable

5.9 m

Inventories

1.2 m2.2 m4.2 m

Current Assets

188.4 m324.6 m219 m547.9 m

PP&E

579 k553 k2.2 m3.1 m

Total Assets

189.1 m325.5 m221.9 m561.2 m

Accounts Payable

372 k2 m1.7 m3.9 m

Current Liabilities

7 m15.8 m21.9 m42.6 m

Total Liabilities

42.7 m

Additional Paid-in Capital

587.7 m807.6 m862.3 m1.5 b

Retained Earnings

(405.7 m)(498.1 m)(662.6 m)(934 m)

Total Equity

182.1 m309.5 m199.8 m518.4 m

Financial Leverage

1 x1.1 x1.1 x1.1 x
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

13.7 m36.4 m76.4 m93.2 m70.8 m175.2 m131.8 m153.7 m157.4 m

Accounts Receivable

293 k3.8 m7.7 m

Inventories

2.9 m4.3 m3.9 m

Current Assets

358.9 m341.1 m299.9 m273.4 m242.8 m462.4 m423.9 m603.5 m489.8 m

PP&E

500 k520 k1.8 m1.8 m2.1 m2.6 m2.9 m3.2 m3.5 m

Total Assets

359.5 m341.8 m302 m275.5 m245.3 m466.6 m438 m617.4 m503 m

Accounts Payable

1.1 m1.1 m2.5 m2.9 m2.2 m1.3 m1 m2.8 m2.2 m

Current Liabilities

9.3 m11.3 m16.7 m19.4 m17.7 m21.1 m29 m39.1 m45.3 m

Additional Paid-in Capital

795 m800.2 m823.6 m833.7 m844.1 m1.2 b1.2 b1.4 b1.5 b

Retained Earnings

(445 m)(469.8 m)(538.5 m)(577.9 m)(616.8 m)(712.3 m)(783.7 m)(855.3 m)(1 b)

Total Equity

350.1 m330.5 m285.1 m255.8 m227.3 m445.3 m408.8 m578.1 m457.5 m

Financial Leverage

1 x1 x1.1 x1.1 x1.1 x1 x1.1 x1.1 x1.1 x
USDFY, 2014FY, 2015FY, 2016

Net Income

(92.5 m)(164.4 m)(271.4 m)

Depreciation and Amortization

206 k647 k1.8 m

Accounts Receivable

(5.9 m)

Inventories

652 k(804 k)(3.3 m)

Accounts Payable

1.6 m(344 k)2.2 m

Cash From Operating Activities

(66.4 m)(121.8 m)(210.4 m)

Purchases of PP&E

(180 k)(2.1 m)(1.5 m)

Cash From Investing Activities

(87.3 m)147.6 m(261.9 m)

Long-term Borrowings

(32 k)

Cash From Financing Activities

203.9 m14.5 m533.8 m

Income Taxes Paid

415 k365 k
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(21.5 m)(24.8 m)(40.4 m)(39.4 m)(38.9 m)(49.8 m)(71.3 m)(71.6 m)(87.8 m)

Accounts Receivable

293 k3.8 m7.7 m

Inventories

2.9 m4.3 m3.9 m

Accounts Payable

1.1 m1.1 m2.5 m2.9 m2.2 m1.3 m1 m2.8 m2.2 m
USDY, 2017

Revenue/Employee

41.3 k

Financial Leverage

1.1 x

ACADIA Pharmaceuticals Operating Metrics

FY, 2016

Patents Issued

302

ACADIA Pharmaceuticals Market Value History

Traffic Overview of ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Company Life and Culture

You may also be interested in